Shutting down deadly paediatric brain cancer at its earliest moments

Pinterest LinkedIn Tumblr +

Cell-by-cell genetic analyses of developing brain tissues in neonatal mice and laboratory models of brain cancer allowed scientists to discover a molecular driver of the highly aggressive, deadly, and treatment-resistant brain cancer – glioblastoma.

Published findings in Cell Stem Cell describe how the single-cell analyses identified a subpopulation of cells critical to glioblastoma formation – the early primitive progenitor cells of oligodendrocyte brain cells, pri-OPC progenitors, according to Q. Richard Lu, PhD, lead investigator and Scientific Director of the Brain tumour Center at Cincinnati Children’s Hospital Medical Center.

The data suggest that reprogramming of primitive oligodendrocyte progenitors into a stem-like state plays an important role in glioma initiation and progression.

The researchers’ primary molecular target in the study, a protein called Zfp36l1, launches biological programs that mirror those of healthy early brain development in the mice, but instead help fuel brain cancer growth.

“The discovery presents an opportunity to find out if new therapeutic approaches can stop glioblastoma at its earliest stages of initial formation or recurrence”, Lu said.

Researchers learned that dysregulation of Zfp36l1 – a protein that binds together different RNAs – causes neural lineage progenitor cells to grow so rapidly that they take on the properties of fast-growing stem-like cells as they turn cancerous.

This was especially true of less-developed primitive oligodendrocyte progenitor cells.

The discovery gave researchers an idea.

“When we used small RNA-interfering molecules to inhibit the expression of the Zpf36l1 gene in mouse and human glioma tumour cells, it significantly decreased the rate of glioma cell growth and spread,” Lu said. “In mice with glioblastoma tumours, genetic knockout of Zpf36l1 significantly increased survival time for the animals.”

Single-cell transcriptomics

The researchers used single-cell transcriptomics as a foundation for their study.

This allowed them to identify, and compare, all of the RNA molecules in each developing glial brain cell and developing cancerous glioblastoma cell.

This included the distinct populations of transitioning oligodendrocyte and astrocyte progenitor cells, particularly the early pri-OPC progenitors that support the rapid growth of glioblastoma.

Researchers said this study is important because prior to the development of new technologies that allow for single-cell analysis, the extremely diverse genetics and types of brain cells that cause high-grade glioblastoma have been hard to nail down.

To determine if their observations in mouse glioma models might apply to tumour formation in human brain tumours, researchers also analysed single-cell transcriptomics of human tumour cells donated by patients.

They found similar populations and genetic signatures in human oligodendrocyte progenitor cells.

The cells had regressed to a less-developed mitotic state and assumed the characteristics of fast-growing stem-like brain cells, setting the stage for tumourigenesis.

Ongoing preclinical research 

The researchers emphasised their data were produced in mice and other laboratory models of brain cancer, so it still remains unknown if the results will translate to patient treatment.

The study does provide important clues, however, for battling a cancer that usually is fatal, including in young children, researchers believe.

Now that Lu and his colleagues know blocking Zfp36l1 function in glioma cells forming from primitive oligodendrocyte progenitor cells inhibits glioblastoma growth in lab models, they are expanding their efforts.

They want to find an effective way to therapeutically exploit what they consider to be a potential new vulnerability for a disease that so far has been invincible.

This includes future work to develop specific therapeutic agents that might more precisely and effectively target Zfp36l1 and the brain cells it helps turn cancerous.

Source: Cincinnati Children’s Hospital Medical Center


About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.